PMID- 29069511
OWN - NLM
STAT- MEDLINE
DCOM- 20190109
LR  - 20231103
IS  - 1745-1701 (Electronic)
IS  - 0586-7614 (Print)
IS  - 0586-7614 (Linking)
VI  - 44
IP  - 4
DP  - 2018 Jun 6
TI  - Negative Symptom Interventions in Youth at Risk of Psychosis: A Systematic Review 
      and Network Meta-analysis.
PG  - 807-823
LID - 10.1093/schbul/sbx139 [doi]
AB  - OBJECTIVE: Youth at clinical high risk (CHR) for psychosis often demonstrate 
      significant negative symptoms, which have been reported to be predictive of 
      conversion to psychosis and a reduced quality of life but treatment options for 
      negative symptoms remain inadequate. Therefore, we conducted a systematic review 
      and network meta-analysis of all intervention studies examining negative symptom 
      outcomes in youth at CHR for psychosis. METHOD: The authors searched PsycINFO, 
      Medline, Embase, CINAHL, and EBM from inception to December 2016. Studies were 
      selected if they included any intervention that reported follow-up negative 
      symptoms in youth at CHR for psychosis. Treatment comparisons were evaluated 
      using both pairwise and network meta-analyses. Due to the differences in negative 
      symptom scales the effect sizes were reported as the standardized mean difference 
      (SMD). RESULTS: Of 3027 citations, 32 studies met our inclusion criteria, 
      including a total of 2463 CHR participants. The null hypothesis was not rejected 
      for any of the 11 treatments. N-methyl-D-aspartate-receptor (NMDAR) modulators 
      trended toward a significant reduction in negative symptoms compared to placebo 
      (SMD = -0.54; 95% CI = -1.09 to 0.02; I2 = 0%, P = .06). In respective order of 
      descending effectiveness as per the treatment hierarchy, NMDAR modulators were 
      more effective than family therapy, need-based interventions, risperidone, 
      amisulpride, cognitive behavioral therapy, omega-3, olanzapine, supportive 
      therapy, and integrated psychological interventions. CONCLUSIONS: Efficacy and 
      effectiveness were not confirmed for any negative symptom treatment. Many studies 
      had small samples and the majority were not designed to target negative symptoms.
FAU - Devoe, Daniel J
AU  - Devoe DJ
AD  - Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, 
      Alberta, Canada.
FAU - Peterson, Aaron
AU  - Peterson A
AD  - Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, 
      Alberta, Canada.
FAU - Addington, Jean
AU  - Addington J
AD  - Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, 
      Alberta, Canada.
LA  - eng
GR  - R01 MH105178/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - United States
TA  - Schizophr Bull
JT  - Schizophrenia bulletin
JID - 0236760
RN  - 0 (Antipsychotic Agents)
SB  - IM
EIN - Schizophr Bull. 2018 Feb 15;44(2):463. PMID: 29462457
MH  - Adolescent
MH  - Adult
MH  - Antipsychotic Agents/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - *Network Meta-Analysis
MH  - Outcome Assessment, Health Care/*statistics & numerical data
MH  - Psychotherapy/*statistics & numerical data
MH  - Psychotic Disorders/drug therapy/physiopathology/*therapy
MH  - Schizophrenia/drug therapy/physiopathology/*therapy
MH  - Young Adult
PMC - PMC6007754
EDAT- 2017/10/27 06:00
MHDA- 2019/01/10 06:00
PMCR- 2019/06/06
CRDT- 2017/10/26 06:00
PHST- 2017/10/27 06:00 [pubmed]
PHST- 2019/01/10 06:00 [medline]
PHST- 2017/10/26 06:00 [entrez]
PHST- 2019/06/06 00:00 [pmc-release]
AID - 4563824 [pii]
AID - sbx139 [pii]
AID - 10.1093/schbul/sbx139 [doi]
PST - ppublish
SO  - Schizophr Bull. 2018 Jun 6;44(4):807-823. doi: 10.1093/schbul/sbx139.